8-K: Journey Medical Announces Q3 2024 Results and FDA Approval of Emrosi

Journey Medical Corporation reported a 4% decrease in revenue for Q3 2024 compared to the same period last year, but also announced the FDA approval of their new drug, Emrosi.

Summary

• Journey Medical Corporation announced its financial results for the third quarter of 2024, reporting total revenues of $14.6 million.
• This represents a 4% decrease in revenue compared to the third quarter of 2023.
• The company experienced a net loss of $2.4 million, or $(0.12) per share, for the quarter, compared to a net income of $16.8 million, or $0.91 per share, in the same period last year.
• Adjusted EBITDA for the quarter was $0.3 million, or $0.01 per share, compared to $20.8 million, or $1.13 per share, in the third quarter of 2023.
• The company's gross product margin increased to 63.9% from 57.9% in the prior year quarter, primarily due to decreased inventory charges and product royalties.
• Research and development costs decreased by $1.4 million due to lower clinical trial expenses for Emrosi.
• Selling, general, and administrative expenses increased by $2.8 million due to higher share-based compensation and marketing expenses, including pre-launch costs for Emrosi.
• The company had $22.5 million in cash and cash equivalents as of September 30, 2024, compared to $23.9 million at June 30, 2024.
• The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults in November 2024, with a launch expected in late Q1 or early Q2 of 2025.

Sentiment

Score: 5

Explanation: The document presents mixed results. While the FDA approval of Emrosi is a significant positive, the decrease in revenue and net loss are concerning. The company's future outlook is dependent on the successful launch of Emrosi.

Positives

• The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults, which is a significant milestone for the company.
• Qbrexza sales increased by 29% due to focused marketing efforts and expanded access.
• The gross product margin increased to 63.9%, driven by lower inventory charges and product royalties.
• Research and development costs decreased by $1.4 million due to lower clinical trial expenses for Emrosi.

Negatives

• Total revenue decreased by 4% compared to the same quarter last year.
• The company reported a net loss of $2.4 million for the quarter.
• Adjusted EBITDA decreased significantly from $20.8 million in Q3 2023 to $0.3 million in Q3 2024.
• Selling, general, and administrative expenses increased by $2.8 million due to higher share-based compensation and marketing expenses.

Risks

• The company's products are subject to regulatory and clinical testing, which may delay or prevent successful commercialization.
• A substantial portion of sales come from products that may face generic competition.
• The company operates in a heavily regulated industry, and future legislation could impact operations.
• The company's revenue is dependent on sales of dermatology products, and any setback could impair results.
• Competition could limit the commercial opportunity and profitability of the company's products.
• The company relies on third parties for several aspects of its operations.
• The company's success depends on the successful commercialization of Emrosi and other future product candidates.
• Clinical drug development is expensive and uncertain, and trials may not demonstrate safety and efficacy.
• The company faces risks related to intellectual property protection.
• The company's business could suffer from computer system failures or cyber-attacks.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may need to raise additional capital.
• Fortress Biotech controls a voting majority of the company's common stock, which could be detrimental to other shareholders.

Future Outlook

The company anticipates continued growth with the expected launch of Emrosi in late first quarter or early second quarter of 2025. They also plan to continue commercializing their core dermatology products.

Management Comments

• Claude Maraoui, Journey Medical's CEO, stated that the FDA approval of Emrosi is a transformational milestone for both the company and the dermatology community.
• Mr. Maraoui also mentioned that the company is completing manufacturing activities and deploying their sales force to enable patient access to Emrosi.

Industry Context

The announcement of Emrosi's FDA approval is significant in the dermatology space, as it positions Journey Medical to compete with existing treatments for rosacea. The company's focus on commercializing FDA-approved prescription products aligns with the broader trend of pharmaceutical companies seeking to bring innovative treatments to market.

Comparison to Industry Standards

• Journey Medical's Q3 2024 revenue of $14.6 million is lower than some of its competitors in the dermatology space, such as Galderma, which reported revenues of $1.02 billion in the first half of 2024. However, Galderma is a much larger company with a broader portfolio.
• The 4% decrease in revenue is not ideal, but the 29% increase in Qbrexza sales shows that the company's marketing efforts are having a positive impact on some products.
• The increase in gross margin to 63.9% is a positive sign, indicating improved efficiency in the company's operations.
• The net loss of $2.4 million is a concern, but it is important to note that the company is investing in the launch of Emrosi, which is expected to drive future growth.
• The adjusted EBITDA of $0.3 million is significantly lower than the $20.8 million reported in the same period last year, but this is largely due to the one-time payment received in Q3 2023.

Management Changes

Related Party Transactions

• The company has a 'Due to related party' liability of $370,000 as of September 30, 2024.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and net loss, but optimistic about the potential of Emrosi.
• Employees will be involved in the launch of Emrosi and the continued commercialization of other products.
• Customers (patients) will benefit from the availability of Emrosi for the treatment of rosacea.
• Suppliers will be involved in the manufacturing and distribution of Emrosi.
• Creditors will be monitoring the company's financial performance and ability to repay debts.

Next Steps

• The company will complete manufacturing activities for Emrosi.
• The company will deploy its sales force to enable patient access to Emrosi.
• The company plans to launch Emrosi in late Q1 or early Q2 of 2025.
• The company will continue to commercialize its core dermatology products.

Key Dates

Keywords

dermatology, pharmaceutical, Emrosi, rosacea, FDA approval, Qbrexza, financial results, revenue, EBITDA, net loss